Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.

Oncotarget - 30 May 2017

Park Mi-Young, Jung Min Hee, Eo Eun Young, Kim Seokjoong, Lee Sang Hoon, Lee Yeon Joo, Park Jong Sun, Cho Young Jae, Chung Jin Haeng, Kim Cheol Hyeon, Yoon Ho Il, Lee Jae Ho, Lee Choon-Taek

Abstract excerpt

Tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are effective against lung adenocarcinomas harboring epidermal growth factor receptor (EGFR) mutations. However, cancer cells can develop resistance to these agents with prolonged exposure; in over 50% of cases, this is attributable to the EGFR T790M mutation. Moreover, additional resistance mutations can arise with the use of new drugs. Cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR-Cas Systems
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Gene Editing

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 28422737
DOI: 10.18632/oncotarget.16752
PMCID: PMC5482658

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.PMID 28422737Read ↗

Potential CRISPR/Cas9 Gene Editing Applications in Reversing Acquired Resistance to EGFR-TKIs due to Secondary and Tertiary Mutations to EGFR in NSCLCSemantic proximity Read ↗

CRISPR-mediated modulation of EGFR signaling in lung cancer.Semantic proximity Read ↗

Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression.Semantic proximity Read ↗

CRISPR/Cas9-Mediated Genome Editing in Cancer TherapySemantic proximity Read ↗

Application of CRISPR/Cas9 Technology in Cancer Treatment: A Future Direction.Semantic proximity Read ↗

CRISPR/Cas9 application in cancer therapy: a pioneering genome editing toolSemantic proximity Read ↗

Engineering CRISPR/Cas9 therapeutics for cancer precision medicineSemantic proximity Read ↗

Integration of CRISPR/Cas9 with artificial intelligence for improved cancer therapeuticsSemantic proximity Read ↗

The Potential Revolution of Cancer Treatment with CRISPR TechnologySemantic proximity Read ↗

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung CancerSemantic proximity Read ↗

Improved EGFR mutation detection sensitivity after enrichment by Cas9/sgRNA digestion and PCR amplification.Semantic proximity Read ↗

CRISPR-Based Fluorescent Reporter (CBFR) Assay for Sensitive, Specific, Inexpensive, and Visual Detection of a Specific EGFR Exon 19 Deletion in NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.